Eton Pharmaceuticals (NASDAQ:ETON) Coverage Initiated at B. Riley

B. Riley began coverage on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a report published on Friday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $21.00 target price on the stock. B. Riley also issued estimates for Eton Pharmaceuticals’ Q1 2025 earnings at $0.03 EPS and Q4 2025 earnings at $0.12 EPS.

A number of other analysts also recently weighed in on the company. Craig Hallum increased their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. HC Wainwright raised their price objective on Eton Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, January 6th.

Eton Pharmaceuticals Price Performance

NASDAQ:ETON opened at $13.44 on Friday. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $15.00. The firm’s 50 day simple moving average is $11.74 and its 200 day simple moving average is $7.48. The company has a market cap of $350.13 million, a PE ratio of -61.09 and a beta of 1.38.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Westside Investment Management Inc. grew its stake in Eton Pharmaceuticals by 5.7% during the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock worth $3,711,000 after purchasing an additional 33,275 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after buying an additional 32,365 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $90,000. Parkman Healthcare Partners LLC grew its position in shares of Eton Pharmaceuticals by 2.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after buying an additional 7,029 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at $54,000. 27.86% of the stock is owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.